LLY vs BIIB
By Alex · Tickerpine
Eli Lilly and Company vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BIIB |
|---|---|---|
| Price | $1,208.12 | $216.03 |
| Market cap | $1.08T | $31.89B |
| P/E ratio | 42.9 | 23.3 |
| ROE | 107.46% | 7.70% |
| Profit margin | 34.99% | 13.80% |
| Revenue growth | 55.50% | 1.90% |
| Dividend yield | 0.57% | — |
| Beta | 0.52 | 0.18 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BIIB in plain English
- LLY is the bigger company — about 33.8× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 23.3 vs 42.9).
- LLY earns a higher return on equity (107% vs 8%).
- LLY is growing revenue faster (56% vs 2%).
- LLY pays a dividend (0.57%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.